

S 3656

Reducing Hereditary Cancer Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 16, 2022

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Feb 16, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/3656>

Sponsor

Name: Sen. Murkowski, Lisa [R-AK]

Party: Republican • **State:** AK • **Chamber:** Senate

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Cardin, Benjamin L. [D-MD]	D · MD		Feb 16, 2022
Sen. Van Hollen, Chris [D-MD]	D · MD		Jul 12, 2022
Sen. King, Angus S., Jr. [I-ME]	I · ME		Jul 14, 2022

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Feb 16, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 4110	Related bill	Jun 24, 2021: Referred to the Subcommittee on Health.

Summary (as of Feb 16, 2022)

Reducing Hereditary Cancer Act of 2022

This bill provides for Medicare coverage of germline mutation testing for individuals with a personal or family history of a hereditary cancer gene mutation or suspected history of hereditary cancer, as well as for associated coverage of risk-reducing surgeries and screenings.

Actions Timeline

- **Feb 16, 2022:** Introduced in Senate
- **Feb 16, 2022:** Read twice and referred to the Committee on Finance.